Synthesis, binding affinity and structure-activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists

Organic and Biomolecular Chemistry

Volumn 13, Issue 8, 2015, Pages 2407-2422

  Junker, Anna ^a   Kokornaczyk, Artur K ^a   Zweemer, Annelien J M ^b   Frehland, Bastian ^a   Schepmann, Dirk ^a   Yamaguchi, Junichiro ^c   Itami, Kenichiro ^c   Faust, Andreas ^d   Hermann, Sven ^d   Wagner, Stefan ^e   Schäfers, Michael ^a,d   Koch, Michael ^f   Weiss, Christina ^f   Heitman, Laura H ^b   Kopka, Klaus ^g   Wünsch, Bernhard ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b LEIDEN UNIVERSITY   (Netherlands)

^c NAGOYA UNIVERSITY   (Japan)

^d INST OF REPRO MED OF THE UNIV   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f BAYER PHARMA AG   (Germany)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

POSITIVE IONS;

4-METHYLPHENYL; AUTOIMMUNE DISEASE; BINDING AFFINITIES; BIOLOGICAL EVALUATION; CHARGED MOIETIES; QUATERNARY AMMONIUM; RECEPTOR ANTAGONISTS; STRUCTURE ACTIVITY RELATIONSHIPS;

BINDING ENERGY;

(7)ANNULENOTHIOPHENE; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CORANNULENE; POLYCYCLIC AROMATIC HYDROCARBON; THIOPHENE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; METABOLISM; MOUSE; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; BINDING SITES; CCR5 RECEPTOR ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; MOLECULAR STRUCTURE; POLYCYCLIC HYDROCARBONS, AROMATIC; RECEPTORS, CCR2; RECEPTORS, CCR5; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 84922804169     PISSN: 14770520     EISSN: None     Source Type: Journal    
DOI: 10.1039/c4ob02397h     Document Type: Article

References (56)

1. J. J. Onuffer R. Horuk Chemokines, chemokine receptors and small-molecule antagonists: recent developments Trends Pharmacol. Sci. 2002 23 459 467
2. S. K. Sanders S. M. Crean P. A. Boxer D. Kellner G. J. LaRosa S. W. Hunt Functional Differences Between Monocyte Chemotactic Protein-1 Receptor A and Monocyte Chemotactic Protein-1 Receptor B Expressed in a Jurkat T Cell J. Immunol. 2000 165 4877 4883
3. R. Martinelli I. Sabroe G. LaRosa T. J. Williams J. E. Pease The CC Chemokine Eotaxin (CCL11) Is a Partial Agonist of CC Chemokine Receptor 2b J. Biol. Chem. 2001 276 42957 42964
4. Y. A. Berchiche S. Gravel M.-E. Pelletier G. St-Onge N. Heveker Different Effects of the Different Natural CC Chemokine Receptor 2b Ligands on β-Arrestin Recruitment, Gαi Signaling, and Receptor Internalization Mol. Pharmacol. 2011 79 488 498
5. V. E. L. Stubbs C. Power K. D. Patel Regulation of eotaxin-3/CCL26 expression in human monocytic cells Immunology 2010 130 74 82
6. M. Feria F. Díaz-González The CCR2 receptor as a therapeutic target Expert Opin. Ther. Pat. 2006 16 49 57
7. R. García-Vicuña M. V. Gómez-Gaviro M. J. Domínguez-Luis M. K. Pec I. González-Alvaro J. M. Alvaro-Gracia F. Díaz-González CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients Arthritis Rheum. 2004 50 3866 3877
8. S. J. Connor N. Paraskevopoulos R. Newman N. Cuan T. Hampartzoumian A. R. Lloyd M. C. Grimm CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the ileum in Crohn's disease Gut 2004 53 1287 1294
9. T. C. Dawson W. A. Kuziel T. A. Osahar N. Maeda Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice Atherosclerosis 1999 143 205 211
10. U. A. Maus K. Waelsch W. A. Kuziel T. Delbeck M. Mack T. S. Blackwell J. W. Christman D. Schlöndorff W. Seeger J. Lohmeyer Monocytes Are Potent Facilitators of Alveolar Neutrophil Emigration During Lung Inflammation: Role of the CCL2-CCR2 Axis J. Immunol. 2003 170 3273 3278
11. T. Sullivan Z. Miao D. J. Dairaghi A. Krasinski Y. Wang B. N. Zhao T. Baumgart L. S. Ertl A. Pennell L. Seitz J. Powers R. Zhao S. Ungashe Z. Wei L. Boring C. L. Tsou I. Charo R. D. Berahovich T. J. Schall J. C. Jaen CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice Am. J. Physiol. Renal Physiol. 2013 305 1288 1297
12. T. J. Sullivan Z. Miao B. N. Zhao L. S. Ertl Y. Wang A. Krasinski M. J. Walters J. P. Powers D. J. Dairaghi T. Baumgart L. C. Seitz R. D. Berahovich T. J. Schall J. C. Jaen Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes Metabolism 2013 62 1623 1632
13. J. Kalliomäki B. Jonzon K. Huizar M. O'Malley A. Andersson D. M. Simpson Evaluation of a novel chemokine receptor 2 (CCR2)-antagonist in painful diabetic polyneuropathy Scand. J. Pain 2013 4 77 83
14. C. Combadiere S. K. Ahuja H. L. Tiffany P. M. Murphy Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES J. Leukoc. Biol. 1996 60 147 152
15. T. N. Wells C. A. Power J. P. Shaw A. E. Proudfoot Chemokine blockers-therapeutics in the making? Trends Pharmacol. Sci. 2006 27 41 47
16. C. Blanpain I. Migeotte B. Lee J. Vakili B. J. Doranz C. Govaerts G. Vassart R. W. Doms M. Parmentier CCR5 Binds Multiple CC-Chemokines: MCP-3 Acts as a Natural Antagonist Blood 1999 94 1899 1905
17. R. Horuk Chemokine receptors Cytokine Growth Factor Rev. 2001 12 313 335
18. H. Deng R. Liu W. Ellmeier S. Choe D. Unutmaz M. Burkhart P. Di Marzio S. Marmon R. E. Sutton C. M. Hill C. B. Davis S. C. Peiper T. J. Schall D. R. Littman N. R. Landau Identification of a major co-receptor for primary isolates of HIV-1 Nature 1996 381 661 666
19. R. Liu W. A. Paxton S. Choe D. Ceradini S. R. Martin R. Horuk M. E. MacDonald H. Stuhlmann R. A. Koup N. R. Landau Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection Cell 1996 86 367 377
20. R. Abdi T. B. Tran A. Sahagun-Ruiz P. M. Murphy B. M. Brenner E. L. Milford D. H. McDermott Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation J. Am. Soc. Nephrol. 2002 13 754 758
21. G. Ahlenstiel T. Berg R. P. Woitas F. Grunhage A. Iwan L. Hess H. H. Brackmann B. Kupfer A. Schernick T. Sauerbruch U. Spengler Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C J. Hepatol. 2003 39 245 252
22. C. Szalai J. Duba Z. Prohaszka A. Kalina T. Szabo B. Nagy L. Horvath A. Csaszar Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1-2518 G/G genotype in CAD patients Atherosclerosis 2001 158 233 239
23. C. R. Balistreri G. Candore M. Caruso E. Incalcaterra C. Franceschi C. Caruso Role of polymorphisms of CC-chemokine receptor-5 gene in acute myocardial infarction and biological implications for longevity Haematologica 2008 93 637 638
24. C. L. Hyde A. MacInnes F. A. Sanders J. F. Thompson R. A. Mazzarella O. Faergeman D. F. van Wijk L. Wood M. Lira S. A. Paciga Genetic Association of the CCR5 Region With Lipid Levels in At-Risk Cardiovascular Patients Circ. Cardiovasc. Genet. 2010 3 162 168
25. C. Weber A. Schober A. Zernecke Chemokines: Key Regulators of Mononuclear Cell Recruitment in Atherosclerotic Vascular Disease Arterioscler. Thromb. Vasc. Biol. 2004 24 1997 2008
26. M. Samson O. Labbe C. Mollereau G. Vassart M. Parmentier Molecular Cloning and Functional Expression of a New Human CC-Chemokine Receptor Gene Biochemistry 1996 35 3362 3367
27. E. L. Gautier C. Jakubzick G. J. Randolph Regulation of the Migration and Survival of Monocyte Subsets by Chemokine Receptors and Its Relevance to Atherosclerosis Arterioscler. Thromb. Vasc. Biol. 2009 29 1412 1418
28. L. Fantuzzi P. Borghi V. Ciolli G. Pavlakis F. Belardelli S. Gessani Loss of CCR2 Expression and Functional Response to Monocyte Chemotactic Protein (MCP-1) During the Differentiation of Human Monocytes: Role of Secreted MCP-1 in the Regulation of the Chemotactic Response Blood 1999 94 875 883
29. A. Kaufmann R. Salentin D. Gemsa H. Sprenger Increase of CCR1 and CCR5 expression and enhanced functional response to MIP-1α during differentiation of human monocytes to macrophages J. Leukocyte Biol. 2001 69 248 252
30. A. Junker, A. Kokornaczyk, A. Strunz and B. Wünsch, Selective and Dual Targeting of CCR2 and CCR5 Receptors: A Current Overview. Springer, Berlin, Heidelberg, 2014, pp. 1-55
31. H. Tokuyama S. Ueha M. Kurachi K. Matsushima F. Moriyasu R. S. Blumberg K. Kakimi The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis Int. Immunol. 2005 17 1023 1034
32. Y.-F. Yang T. Mukai P. Gao N. Yamaguchi S. Ono H. Iwaki S. Obika T. Imanishi T. Tsujimura T. Hamaoka H. Fujiwara A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses Eur. J. Immunol. 2002 32 2124 2132
33. Q. Zhao Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases J. Leukocyte Biol. 2010 88 41 55
34. L. Boring J. Gosling M. Cleary I. F. Charo Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis Nature 1998 394 894 897
35. J. Lalezari J. Gathe C. Brinson M. Thompson C. Cohen E. Dejesus J. Galindez J. A. Ernst D. E. Martin S. M. Palleja Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects J. Acquir. Immune Defic. Syndr. 2011 57 118 125
36. C. Zheng G. Cao M. Xia H. Feng J. Glenn R. Anand K. Zhang T. Huang A. Wang L. Kong M. Li L. Galya R. O. Hughes R. Devraj P. A. Morton D. J. Rogier M. Covington F. Baribaud N. Shin P. Scherle S. Diamond S. Yeleswaram K. Vaddi R. Newton G. Hollis S. Friedman B. Metcalf C. B. Xue Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist Bioorg. Med. Chem. Lett. 2011 21 1442 1446
37. M. Shiraishi Y. Aramaki M. Seto H. Imoto Y. Nishikawa N. Kanzaki M. Okamoto H. Sawada O. Nishimura M. Baba M. Fujino Discovery of Novel, Potent, and Selective Small-Molecule CCR5 Antagonists as Anti-HIV-1 Agents: Synthesis and Biological Evaluation of Anilide Derivatives with a Quaternary Ammonium Moiety J. Med. Chem. 2000 43 2049 2063
38. M. Seto K. Aikawa N. Miyamoto Y. Aramaki N. Kanzaki K. Takashima Y. Kuze Y. Iizawa M. Baba M. Shiraishi Highly Potent and Orally Active CCR5 Antagonists as Anti-HIV-1 Agents: Synthesis and Biological Activities of 1-Benzazocine Derivatives Containing a Sulfoxide Moiety J. Med. Chem. 2006 49 2037 2048
39. A. Junker D. Schepmann J. Yamaguchi K. Itami A. Faust K. Kopka S. Wagner B. Wunsch Diverse modifications of the 4-methylphenyl moiety of TAK-779 by late-stage Suzuki-Miyaura cross-coupling Org. Biomol. Chem. 2014 12 177 186
40. A. Junker J. Yamaguchi K. Itami B. Wünsch Synthesis of Thiophene-Based TAK-779 Analogues by C-H Arylation J. Org. Chem. 2013 78 5579 5586
41. B. Join T. Yamamoto K. Itami Iridium catalysis for C-H bond arylation of heteroarenes with iodoarenes Angew. Chem., Int. Ed. 2009 48 3644 3647
42. R. H. Crabtree M. W. Davis Occurrence and Origin of a Pronounced Directing Effect of a Hydroxyl Group in Hydrogenation with [Ir(cod)P-c-Hx3,(py)]PF6 Organometallics 1983 2 681 682
43. D. A. Evans G. C. Fu Amide-Directed, Iridium-Catalyzed Hydroboration of Olefins: Documentation of Regio- and Stereochemical Control in Cyclic and Acyclic Systems J. Am. Chem. Soc. 1991 113 4042 4043
44. A. J. M. Zweemer I. Nederpelt H. Vrieling S. Hafith M. L. J. Doornbos H. de Vries J. Abt R. Gross D. Stamos J. Saunders M. J. Smit A. P. IJzerman L. H. Heitman Multiple Binding Sites for Small-Molecule Antagonists at the CC Chemokine Receptor 2 Mol. Pharmacol. 2013 84 551 561
45. P. M. Murphy M. Baggiolini I. F. Charo C. A. Hébert R. Horuk K. Matsushima L. H. Miller J. J. Oppenheim C. A. Power International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors Pharmacol. Rev. 2000 52 145 176
46. J. Aliberti J. G. Valenzuela V. B. Carruthers S. Hieny J. Andersen H. Charest C. Reis e Sousa A. Fairlamb J. M. Ribeiro A. Sher Molecular mimicry of a CCR5 binding-domain in the microbial activation of dendritic cells Nat. Immunol. 2003 4 485 490
47. K. Maeda D. Das H. Ogata-Aoki H. Nakata T. Miyakawa Y. Tojo R. Norman Y. Takaoka J. Ding G. F. Arnold E. Arnold H. Mitsuya Structural and Molecular Interactions of CCR5 Inhibitors with CCR5 J. Biol. Chem. 2006 281 12688 12698
48. G. Kothandan C. G. Gadhe S. J. Cho Structural Insights from Binding Poses of CCR2 and CCR5 with Clinically Important Antagonists: A Combined In Silico Study PLoS One 2012 7 e32864
49. C. B. Xue, B. Metcalf, H. Feng, G. Cao, T. Huang, C. Zheng, D. J. Robinson and A. Q. Han, 3-Aminopyrrolidine derivatives as modulators of chemokine receptors, WO2004050024 A2, 2004. June, 17, 2004
50. C. M. Brodmerkel R. Huber M. Covington S. Diamond L. Hall R. Collins L. Leffet K. Gallagher P. Feldman P. Collier M. Stow X. Gu F. Baribaud N. Shin B. Thomas T. Burn G. Hollis S. Yeleswaram K. Solomon S. Friedman A. Wang C. B. Xue R. C. Newton P. Scherle K. Vaddi Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344 J. Immunol. 2005 175 5370 5378
51. Y. Cheng W. H. Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 1973 22 3099 3108
52. R. A. Glennon Mini-Rev. Med. Chem. 2005 5 927 940
53. R. A. Glennon S. Y. Ablordeppey A. M. Ismaiel M. B. Elashmawy J. B. Fischer K. B. Howie J. Med. Chem. 1994 37 1214 1219
54. 1 Receptor Curr. Pharm. Des. 2012 18 930 937
55. C. A. Maier B. Wünsch Novel σ receptor ligands. Part 2. SAR of spiro[[2]benzopyran-1,4′-piperidines] and spiro[[2]benzofuran-1,4′-piperidines] with carbon substituents in position 3 J. Med. Chem. 2002 45 4923 4930
56. 1 receptor affinity by late-stage C-H-bond arylation of spirocyclic lactones Bioorg. Med. Chem. 2013 21 1844 1856